Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Biotron Limited

Healthcare US BITRF

0.002USD
0.00(0%)

Last update at 2026-06-22T20:00:00Z

Day Range

0.0020.002
LowHigh

52 Week Range

0.00110.03
LowHigh

Fundamentals

  • Previous Close 0.002
  • Market Cap8.11M
  • Volume300000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.96858M
  • Revenue TTM-0.00087M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.00087M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -0.31857M -3.43652M -4.92349M -2.78108M -3.19435M
Minority interest - - - - -
Net income -0.31857M -3.43652M -3.49277M -2.78108M -3.19435M
Selling general administrative 0.77M 0.53M 1.63M 1.12M 1.13M
Selling and marketing expenses 0.74M 0.87M - - -
Gross profit 1.81M 1.60M 1.39M 1.51M 1.41M
Reconciled depreciation - - 0.04M 0.05M 0.05M
Ebit -0.33875M -3.50606M -3.48838M -2.77603M -3.19309M
Ebitda -0.33381M -3.50449M -3.44503M -2.73078M -3.14575M
Depreciation and amortization 0.00494M 0.00157M 0.04M 0.05M 0.05M
Non operating income net other - - - - -
Operating income -0.33875M -3.50606M -5.03876M -2.77603M -3.19309M
Other operating expenses 2.15M 5.15M 5.04M 4.34M 4.67M
Interest expense - 0.00109M 0.00439M 0.00505M 0.00126M
Tax provision - - 0.00000M 0.00000M 0.00000M
Interest income - - 0.12M 0.00309M 0.01M
Net interest income - - 0.12M -0.00196M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -1.64511M -1.43073M 1.56M 1.46M
Total revenue 1.81M 1.65M 1.43M 1.56M 1.46M
Total operating expenses 2.15M 5.15M 5.00M 4.34M 4.67M
Cost of revenue - 0.04M 0.04M 0.05M 0.05M
Total other income expense net 0.02M 0.07M 0.12M -0.00196M 0.01M
Discontinued operations - - - - -
Net income from continuing ops - - -3.49277M -2.78108M -3.19435M
Net income applicable to common shares - - -3.49277M -2.78108M -3.19435M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 0.98M 0.49M 4.14M 1.91M 4.33M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.02M 0.03M 0.02M 0.02M 0.05M
Total liab 0.43M 0.74M 0.96M 0.81M 0.46M
Total stockholder equity 0.55M -0.24403M 3.17M 1.09M 3.86M
Deferred long term liab - - - - -
Other current liab 0.34M 0.44M - 0.33M 0.31M
Common stock 59.32M 56.91M 56.89M 52.84M 52.84M
Capital stock - - 56.89M 52.84M 52.84M
Retained earnings -58.77283M -58.68079M -55.26377M -51.83737M -49.08691M
Other liab - - - 0.02M 0.01M
Good will - - - - -
Other assets - - 0.05M 0.05M 0.03M
Cash 0.93M 0.39M 3.98M 1.74M 4.21M
Cash and equivalents - - - - -
Total current liabilities 0.43M 0.74M 0.96M 0.75M 0.45M
Current deferred revenue - - - - -
Net debt -0.93168M -0.38607M - -1.66417M -4.20428M
Short term debt - 0.00713M - 0.03M 0.00635M
Short long term debt - - - - -
Short long term debt total - 0.00713M - 0.08M 0.00635M
Other stockholder equity - 1.52M 0.02M 0.09M 0.11M
Property plant equipment - - 0.05M 0.09M 0.03M
Total current assets 0.96M 0.43M 4.03M 1.76M 4.26M
Long term investments - - - - -
Net tangible assets - - 3.17M 1.09M 3.86M
Short term investments - - - - -
Net receivables - 0.02M 0.02M - -
Long term debt - - - - -
Inventory - -0.00276M - - -
Accounts payable 0.09M 0.29M 0.29M 0.39M 0.14M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.00000M - 0.09M 0.11M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.02M 0.05M 0.05M 0.05M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 0.03M 0.07M 0.10M 0.14M 0.06M
Capital lease obligations - - 0.05M 0.08M 0.00635M
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - - - - -0.00572M
Change to liabilities - - 0.15M 0.20M -0.36541M
Total cashflows from investing activities -0.00307M - - - -0.00572M
Net borrowings - - -0.03991M -0.03317M -0.03696M
Total cash from financing activities 1.11M -0.02262M 5.53M -0.03317M -0.03696M
Change to operating activities - - -0.02595M 0.01M 0.00718M
Net income -0.31857M -3.43652M -3.49277M -2.78108M -3.19435M
Change in cash 0.54M -3.59119M 2.24M -2.46922M -3.45028M
Begin period cash flow 0.39M 3.98M 1.74M 4.21M 7.66M
End period cash flow 0.93M 0.39M 3.98M 1.74M 4.21M
Total cash from operating activities -0.56580M -3.56857M -3.29004M -2.43605M -3.40760M
Issuance of capital stock - - 6.00M - -
Depreciation 0.01M 0.04M 0.04M 0.05M 0.05M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - -0.42780M - -
Other cashflows from financing activities 1.11M 0.02M -0.03991M -0.03317M -0.03696M
Change to netincome - - 0.04M 0.09M 0.10M
Capital expenditures 0.00307M 0.00000M 0.00000M 0.00000M 0.00572M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.00991M 0.04M 0.12M 0.21M -0.35824M
Stock based compensation - - - 0.01M 0.08M
Other non cash items -0.26824M -0.13204M 0.04M 0.09M 0.10M
Free cash flow -0.56887M -3.56857M -3.29004M -2.43605M -3.41332M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BITRF
Biotron Limited		 - -% 0.002 - - 1010.23 44.87 238.66 11.27
NVO
Novo Nordisk A/S		 1.15 2.51% 47.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.41 0.30% 468.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.50 1.06% 619.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.

Biotron Limited

66 Hunter Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Exec. Director NA
Mr. Peter James Nightingale B.Econ, CA Company Sec. 1957
Dr. Stephen L. Becker M.D. Chief Medical Officer NA
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Executive Director NA
Mr. Peter James Nightingale B.Econ, CA Company Secretary 1957
Mr. Marcelo Mora ACIS, B.Bus Aasa Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions